Long-Time Horizon Analysis of DiaMedica Therapeutics Inc (DMAC) Stock

At the time of writing, DiaMedica Therapeutics Inc [DMAC] stock is trading at $4.54, up 8.61%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The DMAC shares have gain 13.22% over the last week, with a monthly amount glided 18.85%, and seem to be holding up well over a long-time horizon.

From an analyst’s perspective:

DiaMedica Therapeutics Inc [NASDAQ: DMAC] stock has seen the most recent analyst activity on October 07, 2024, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $7. On June 22, 2023, upgrade upgraded it’s rating to Outperform but maintained its price target of $7 on the stock. Oppenheimer started tracking the stock assigning a Outperform rating and suggested a price target of $27 on April 09, 2021. ROTH Capital initiated its recommendation with a Buy and recommended $38 as its price target on February 17, 2021. Guggenheim started tracking with a Buy rating for this stock on October 30, 2020, and assigned it a price target of $16. In a note dated July 08, 2020, Maxim Group initiated an Buy rating and provided a target price of $14 on this stock.

For the past year, the stock price of DiaMedica Therapeutics Inc fluctuated between $3.19 and $6.82. Currently, Wall Street analysts expect the stock to reach $8.33 within the next 12 months. DiaMedica Therapeutics Inc [NASDAQ: DMAC] shares were valued at $4.54 at the most recent close of the market. An investor can expect a potential return of 83.48% based on the average DMAC price forecast.

Analyzing the DMAC fundamentals

To continue investigating profitability, this company’s Return on Assets is posted at -0.7, Equity is -0.61 and Total Capital is -0.85. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.

Ratios To Look Out For

It is important to note that DiaMedica Therapeutics Inc [NASDAQ:DMAC] has a current ratio of 8.02. As well, the Quick Ratio is 8.02, while the Cash Ratio is 0.55.

Related Posts

MZP News
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.